The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Metformin
Placebo
Sponsored by

About this trial
This is an interventional basic science trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- male
- HbA1c < 39 mmol/l
- BMI < 25
- structured physical activity < = 150 min/week
- apparently healthy
Exclusion Criteria:
- smoking
- daily pharmaceutical treatment
- contraindication to increased levels of physical activity
- ALAT/ASAT elevated 3 times above upper normal values
- renal insufficiency (eGFR < 60 ml/min)
- prior history of lactic acidosis
Sites / Locations
- Center for aktiv sundhed
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Metformin
Placebo
Arm Description
17 days metformin treatment
17 days placebo treatment
Outcomes
Primary Outcome Measures
Overall aerobic work performed during an exercise bout with self-selected intensity
Secondary Outcome Measures
External work performed during an exercise bout with self-selected intensity
Rate of perceived exertion during an exercise bout with fixed intensity
blood lactate during an exercise bout with fixed intensity
Heartrate during an exercise bout with fixed intensity
Respiratory exchange ratio during an exercise bout with fixed intensity
Physical fitness (VO2max)
Full Information
NCT ID
NCT02951260
First Posted
October 27, 2016
Last Updated
September 26, 2017
Sponsor
Rigshospitalet, Denmark
Collaborators
University of Copenhagen
1. Study Identification
Unique Protocol Identification Number
NCT02951260
Brief Title
The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation
Official Title
The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation
Study Type
Interventional
2. Study Status
Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
October 2016 (Actual)
Primary Completion Date
April 2017 (Actual)
Study Completion Date
July 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark
Collaborators
University of Copenhagen
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the potential interaction between metformin and exercise in order to optimize clinical guidelines for treatment of T2D.
Detailed Description
Physical activity is a first line treatment for patients with type 2 diabetes (T2D ), however, the vast majority of patients with T2D do not achieve satisfying glycemic control with physical activity alone, which is why pharmacological treatment with metformin is most often initiated. It is known that metformin and exercise both activates AMPK, which results in many different metabolic effects. Because of this similarity, an interaction between metformin and exercise is plausible, but knowledge in the area is sparse. With this study the investigators aim to look at the individual and combined effects of metformin and exercise in order to investigate whether an interaction occur. An Interaction will have tremendous clinical importance for patients with T2D given current guidelines where the vast majority of these patients are recommended both exercise and metformin treatment.
The investigators hypothesize that metformin treatment reduces self-selected exercise intensity, which may be explained via decreased mitochondrial complex 1 function, increased blood lactate levels, heart rate and RPE during exercise. Furthermore exercise-induced AMPK-activation is reduced with metformin treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Metformin
Arm Type
Experimental
Arm Description
17 days metformin treatment
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
17 days placebo treatment
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
17 days treatment with metformin
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
17 days treatment with placebo
Primary Outcome Measure Information:
Title
Overall aerobic work performed during an exercise bout with self-selected intensity
Time Frame
Total oxygen consumption (L O2) during a 45 min ergometer cycling bout with self-selected intensity
Secondary Outcome Measure Information:
Title
External work performed during an exercise bout with self-selected intensity
Time Frame
Total work produced (kJ) during a 45 min ergometer cycling bout with self-selected intensity
Title
Rate of perceived exertion during an exercise bout with fixed intensity
Time Frame
Mean rate of perceived exertion (Borg scale) during a 45 min ergometer cycling bout with fixed intensity
Title
blood lactate during an exercise bout with fixed intensity
Time Frame
Mean blood lactate (mmol/l) during a 45 min ergometer cycling bout with fixed intensity
Title
Heartrate during an exercise bout with fixed intensity
Time Frame
Mean heart rate (bpm) during a 45 min ergometer cycling bout with fixed intensity
Title
Respiratory exchange ratio during an exercise bout with fixed intensity
Time Frame
Mean VCO2/VO2 during a 45 min ergometer cycling bout with fixed intensity
Title
Physical fitness (VO2max)
Time Frame
maximal oxygen consumption (L/min) during a VO2 max test
Other Pre-specified Outcome Measures:
Title
AMPK-activation in skeletal muscle during an exercise bout with fixed intensity
Time Frame
change in exercise induced AMPK-activation after compared to before a 45 min ergometer cycling bout with self-selected intensity
Title
Oxidative phosphorylation in skeletal muscle fibers
Time Frame
Mitochondrial Complex I respiration in skeletal muscle tissue after 17 days of metformin/placebo treatment
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
male
HbA1c < 39 mmol/l
BMI < 25
structured physical activity < = 150 min/week
apparently healthy
Exclusion Criteria:
smoking
daily pharmaceutical treatment
contraindication to increased levels of physical activity
ALAT/ASAT elevated 3 times above upper normal values
renal insufficiency (eGFR < 60 ml/min)
prior history of lactic acidosis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristian Karstoft, MD, PhD
Organizational Affiliation
Center for aktiv sundhed, Rigshospitalet
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for aktiv sundhed
City
Copenhagen
State/Province
Copenhagen N
ZIP/Postal Code
2200
Country
Denmark
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
34784247
Citation
Pilmark NS, Oberholzer L, Halling JF, Kristensen JM, Bonding CP, Elkjaer I, Lyngbaek M, Elster G, Siebenmann C, Holm NFR, Birk JB, Larsen EL, Lundby AM, Wojtaszewski J, Pilegaard H, Poulsen HE, Pedersen BK, Hansen KB, Karstoft K. Skeletal muscle adaptations to exercise are not influenced by metformin treatment in humans: secondary analyses of 2 randomized, clinical trials. Appl Physiol Nutr Metab. 2022 Mar;47(3):309-320. doi: 10.1139/apnm-2021-0194. Epub 2021 Nov 16.
Results Reference
derived
Learn more about this trial
The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation
We'll reach out to this number within 24 hrs